Drug reference
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures | Treatment of corticosteroid-induced osteoporosis ▶BY SUBCUTANEOUS INJECTION ▶Adult: 20 micrograms daily for maximum duration of treatment 24 months (course not to be repeated)
PDF page 795
Bone metastases. hyperparathyroidism. metabolic bone diseases. Paget’s disease. pre-existing hypercalcaemia. previous radiation therapy to the skeleton. skeletal malignancies. unexplained raised alkaline phosphatase
PDF page 795
Teriparatide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.
PDF page 795
NICE decisions ▶Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (updated February 2018) NICE TA161 Teriparatide is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women: . who are unable to take alendronate and risedronate, or have a contra-indication to or are intolerant of Endocrine system alendronate and risedronate, or have had an unsatisfactory response to treatment with alendronate or risedronate, and . who are 65 years or older and have a T-score of -4 standard deviations (SD) or below, or a T-score of -3.5 SD or below plus more than two fractures, or who are aged 55-64 years and have a T-score of -4 SD or below plus more than two fractures. Women who are currently receiving treatment, but for whom treatment would not have been recommended, should have the option to continue treatment until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta161
PDF page 796
▶Common or very common Anaemia. asthenia. chest pain. gastrointestinal disorders. headache. hypercholesterolaemia. hyperhidrosis. hypotension. muscle complaints. palpitations. sciatica. skin reactions. syncope. vomiting ▶Uncommon Arthralgia. back pain. emphysema. hypercalcaemia. hyperuricaemia. nephrolithiasis. tachycardia. urinary disorders. weight increased ▶Rare or very rare Oedema. renal impairment
PDF page 795
Avoid.
PDF page 795
Avoid.
PDF page 795
Caution in moderate impairment; avoid if severe.
PDF page 795
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Forsteo (Eli Lilly and Company Ltd) Teriparatide 250 microgram per 1 ml Forsteo 20micrograms/80microlitres solution for injection 2.4ml pre-filled pens | 1 pre-filled disposable injection P £271.88 DT = £271.88 ▶Movymia (Thornton & Ross Ltd) Teriparatide 250 microgram per 1 ml Movymia 20micrograms/80microlitres solution for injection 2.4ml cartridge with pen | 1 cartridge P £235.00 | Movymia 20micrograms/ 80microlitres solution for injection 2.4ml cartridge | 1 cartridge P £235.00 ▶Terrosa Gedeon Richter (UK) Ltd) Teriparatide 250 microgram per 1 ml Terrosa 20micrograms/80microlitres solution for injection 2.4ml cartridge | 1 cartridge P £239.25 | 3 cartridge P £717.75 | Terrosa 20micrograms/80microlitres solution for injection 2.4ml cartridge with pen | 1 cartridge P £239.25 DRUGS AFFECTING BONE STRUCTURE AND MINERALISATION › MONOCLONAL ANTIBODIES
PDF page 796
20 micrograms daily for maximum duration of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 795
